Introduction

Materials and Methods
• Six human serum pools were created (mean concentration):
-High (>2000 pg/mL) -Normal (324 pg/mL) IFBA Positive -Low (85 pg/mL) -High (>2000 pg/mL) -Normal (392 pg/mL) IFBA Negative -Low (159 pg/mL) Total cobalamin determined by Centaur XP Cobalamin reference interval (210-911 pg/mL) IFBA determined by ELISA, INOVA Diagnostics
• All serum pools were tested before and after serum immunoglobulin precipitation by 1:2 dilution with 25% polyethylene glycol (PEG) for total serum cobalamin, and for IFBA to confirm immunoglobulin precipitation.
• Sample pools were tested in triplicate on the same day by the following analyzers: Centaur XP and IM-MULITE 2000 (Siemens Healthcare Diagnostics), ARCHITECT i2000SR (Abbott Diagnostics), UniCel DxI 800 (Beckman Coulter Inc.), and Modular E170 (Roche Diagnostics). Kits donated by mfgs. listed.
• Total allowable error of mean ± 30% was used to evaluate changes in cobalamin concentrations.
• Serum from a patient with IFBA and untreated pernicious anemia which had previously generated false normal results with the Siemens Dimension Vista was tested untreated and PEG-treated with a representative assay (Centaur XP).
Results
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Several authors have recently reported false normal cobalamin (vitamin B12) results in patients diagnosed with pernicious anemia. Interference of native intrinsic factor blocking antibody (IFBA) with automated immunoassays, due to oxidized dithiothreitol, has been proposed as a cause of these falsely elevated results. Interference with cobalamin results is a concern, since almost 70% of pernicious anemia patients test positive for IFBA.
Conclusions
• Five automated cobalamin assays were evaluated; none showed a significant decrease in cobalamin concentration (mean ± 30%) after immunoglobulin precipitation by PEG.
• This was illustrated in serum pools, regardless of cobalamin concentration, along with a sample from a patient with untreated pernicious anemia which had previously generated false normal results with the Siemens Dimension Vista.
• Similar recoveries, regardless of IFBA presence or cobalamin concentration, suggest that these five automated cobalamin assays do not cross-react with IFBA.
While all results should be correlated with clinical signs and symptoms, laboratories may use this information to monitor clinical assay performance.
Objective
In light of a recent voluntary vendor recall of cobalamin reagent due to IFBA interference, our objective was to investigate five additional automated cobalamin immunoassays to determine if they were similarly affected. • PEG treatment reduced IFBA results by 99%, which confirmed immunoglobulin precipitation.
• The average difference in measureable cobalamin concentration between the six untreated and PEG-treated pools using the five immunoassays was 16.9% (range 4.0 to 38.6%).
• All PEG-treated results were within the total allowable error (mean ± 30%) of the untreated pools, with one exception (low cobalamin -IFBA positive pool by the Centaur XP; 38.6%), however both treated and untreated pools would have qualitatively been classified as cobalamin deficient (<120 pg/mL).
• The low cobalamin -IFBA positive sample pool was below the AMR by the DxI (50 pg/mL) after PEG treatment. Correcting for dilution (x2), the sample result was presumed within the total allowable error of mean ± 30% (52 -97 pg/mL).
• Similar results were observed for both the low and normal cobalamin -(IFBA positive and negative) pools when tested with the IMMULITE 2000. The lower limit of the AMR is 150 pg/mL, therefore correcting for dilution (x2) the normal cobalamin sample pools were presumed within the total allowable error of mean ± 30% (218 to 404 pg/mL and 272 to 506 pg/mL for IFBA positive and negative, respectively). Vertical bars represent the range of total allowable error (untreated mean ± 30%), followed by dashes representing PEG-treated pool means corrected for dilution (x2). Results for low and normal cobalamin, IFBA positive and negative, pools are shown. High cobalamin pools (IFBA positive and negative) tested above the AMR for all assays before and after PEG treatment, and thus are not shown.
Results
(Right) A sample from a patient with pernicious anemia and IFBA. Untreated and PEG-treated cobalamin results did not differ from each other using the Centaur XP. Conversely, spuriously elevated cobalamin concentration previously obtained by the Dimension Vista was rectified after precipitation by PEG (1735 pg/mL to <50 pg/mL).
